- On Saturday, for the first time in its roughly two-year history, e-cigarette company Juul presented some data from a clinical trial of its devices.
- The company has a reputation for aggressively marketing its dessert-flavored nicotine products to teens, some of whom, research suggests, may now be at a higher risk of using regular cigarettes.
- But Juul, which is now partially owned by Marlboro maker Altria, is now conducting scientific research.
- In general, that research is considered a key step toward ensuring that a new product is not causing undo harm to people.
- But the study still leaves many unanswered questions about the overall health of vaping, and also leaves unaddressed the issue of use by teens.
On Saturday the company, which is now partially owned by Marlboro maker Altria, presented a poster summary of a clinical trial comparing people who exclusively used its devices against people who smoked traditional cigarettes at an annual meeting for the Society for Research on Nicotine and Tobacco.See the rest of the story at Business Insider
- A new Medicare payment model will likely spur telemedicine adoption and reduce costs
- Pharma giants like Novartis and Sanofi are betting that the future of healthcare looks more like an app or sensor than a prescription
- A controversial startup that was charging $8,000 to fill your veins with young blood says it’s halted operations after a warning from regulators